Related Experiment Video

Updated: Oct 9, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

Pharmacotherapy following myocardial infarction--a review of current treatment practices

S Ørn1, K Dickstein

  • 1Cardiology Division, Central Hospital, Rogaland, N-4003 Stavanger, Norway.

Expert Opinion on Pharmacotherapy
|March 16, 2001
PubMed

Insights

Effective secondary prevention after acute myocardial infarction (AMI) using medications like aspirin and statins improves outcomes. However, underuse of these strategies challenges mortality reduction in coronary artery disease (CAD) management.

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Modern acute myocardial infarction (AMI) treatments reduce mortality but increase the need for ongoing medical management.
  • Established post-infarction therapies, including aspirin, statins, beta-blockers, and ACE inhibitors, are cost-effective and improve patient morbidity and mortality.
  • Significant progress in secondary prevention has been achieved in preventing reinfarction, recurrent ischemia, and heart failure development.

Purpose of the Study:

  • To highlight the challenges in implementing established medical strategies for secondary prevention after myocardial infarction (MI).
  • To emphasize the ongoing high mortality rates despite advances, often due to underutilization of proven treatments.
  • To underscore the importance of preventing the underlying coronary artery disease (CAD) as the primary objective.

Main Methods:

  • Review of current medical treatment strategies for acute myocardial infarction (AMI) and secondary prevention.
  • Analysis of the impact of established pharmacological interventions on morbidity and mortality post-MI.
  • Discussion of implementation challenges and the evolving landscape of early invasive strategies.

Main Results:

  • While mortality rates have decreased with modern AMI treatments, a significant number of patients require long-term medical care.
  • Post-MI pharmacotherapy has demonstrated efficacy in reducing reinfarction, recurrent ischemia, and heart failure.
  • Underuse of documented medical strategies contributes to persistent high mortality rates.

Conclusions:

  • Despite advances in AMI treatment and secondary prevention, high mortality persists due to suboptimal implementation of evidence-based medical strategies.
  • The integration of current treatment protocols into general practice remains a significant clinical challenge.
  • Preventing coronary artery disease (CAD) and optimizing secondary prevention post-MI are critical for future cardiovascular health outcomes.

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...